Article Text

other Versions

Download PDFPDF
Paper
Disclosure of individual research results in clinico-genomic trials: challenges, classification and criteria for decision-making
  1. Regine Kollek,
  2. Imme Petersen
  1. University of Hamburg, Research Centre for Biotechnology, Society and the Environment, Research Group on Medicine and Neurosciences, Falkenried, Hamburg, Germany
  1. Correspondence to Dr Imme Petersen, University of Hamburg, Research Centre for Biotechnology, Society and the Environment, Research Group on Medicine and Neuroscience, Lottestrasse 55, D-22529 Hamburg, Germany; imme.petersen{at}uni-hamburg.de

Abstract

While an ethical obligation to report findings of clinical research to trial participants is increasingly recognised, the academic debate is often vague about what kinds of data should be fed back and how such a process should be organised. In this article, we present a classification of different actors, processes and data involved in the feedback of research results pertaining to an individual. In a second step, we reflect on circumstances requiring further ethical consideration. In regard to a concrete research setting—the one of clinico-genomic research—we discuss what kinds of difficulties have to be faced when returning individual research results to trial participants. In a last step, we elaborate on a stepwise model to trigger the individual feedback process. Hence, this paper gives guidance on how to feedback individual research results in a specific research setting and responds at the same time to new challenges in the debate on the duty to return individual research findings.

  • Disclosure
  • access to information
  • genomics
  • research subjects
  • philosophical ethics
  • confidentiality/privacy
  • truth disclosure

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding This work is part of the project 'ACGT – Advancing Clinico-Genomic Trials on Cancer' (http://www.eu-acgt.org/), supported by the 6th European Research Framework Programme (grant number: FP6-IST-026996).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Other content recommended for you